<DOC>
	<DOC>NCT01377233</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of once weekly dosing of zicronapine, compared to daily dosing of zicronapine.</brief_summary>
	<brief_title>Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia</brief_title>
	<detailed_description>The study includes 2 treatment periods. The open-label run-in period will begin at patient enrolment and continue for 3 weeks, during which all patients will receive once daily treatment with zicronapine. The double-blind period will begin at patient randomization and continue for 5 weeks, during which the patients will be assigned to one group receiving once daily treatment with zicronapine and 3 groups receiving once weekly treatment with zicronapine.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSMIVTR) A score of &lt;=4 (moderately ill) on Clinical Global Impression Severity of Illness (CGIS) scale A total score &gt;=60 on Positive and Negative Syndrome Scale (PANSS) A score of &lt;=4 (moderate) on PANSS items: P7 (hostility) AND G8 (uncooperativeness) Acute exacerbation requiring hospitalization within the last 3 months OR requiring change of antipsychotic medication within the last 4 weeks Diagnosis or history of substance dependence or substance abuse according to DSMIVTR within the last 3 months Significant risk of harming himself/herself or others Positive serology for hepatitis A, B, C, or HIV Present condition that might compromise liver function Medical or neurological disorder or treatment that could interfere with study treatment or compliance Previous exposure to zicronapine Other inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Zicronapine</keyword>
	<keyword>Lu 31-310</keyword>
</DOC>